Revenue ($USD) : $493,632,000
R&D spend : $87,533,000
Employees : 1,300
Fiscal year end : 12/31/2023
CEO : Drew Hykes

www.inarimedical.com

Inari Medical develops thrombectomy systems for treating venous diseases such as venous thromboembolism. Its devices include the ClotTriever for capturing and removing large clot burden from big vessels and FlowTriever for retrieval and aspiration when treating pulmonary embolism (PE). In 2023, Inari expanded its portfolio with its $415 million acquisition of LimFlow, which won FDA premarket approval the same year for its breakthrough Transcatheter Arterialization of Deep Veins (TADV) system to treat chronic limb-threatening ischemia (CLTI). –SW and JH